Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methyldopa
Drug ID BADD_D01425
Description Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.[A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals.[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form.[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].[L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624]
Indications and Usage For use in the treatment of hypertension.
Marketing Status Prescription; Discontinued
ATC Code C02AB01
DrugBank ID DB00968
KEGG ID D00405
MeSH ID D008750
PubChem ID 38853
TTD Drug ID D0BA6T
NDC Product Code 15894-0038; 42185-7001; 16729-031; 52423-0100; 16729-030; 67628-3001
Synonyms Methyldopa | alpha-Methyldopa | alpha Methyldopa | alpha-Methyl-L-Dopa | alpha Methyl L Dopa | Alphamethyldopa | Meldopa | Methyldopate | Dopegyt | Dopergit | Dopegit | Sembrina | Apo-Methyldopa | Apo Methyldopa | Dopamet | Aldomet | Hydopa | Nu-Medopa | Nu Medopa
Chemical Information
Molecular Formula C10H13NO4
CAS Registry Number 555-30-6
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sepsis11.01.11.0030.001228%
Sialoadenitis11.01.04.002; 07.06.04.002--
Sinus bradycardia02.03.03.0090.004706%
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.0060.007059%
Stillbirth18.01.02.002; 08.04.01.0060.001228%Not Available
Suicide attempt19.12.01.0040.004706%
Tachycardia02.03.02.0070.004706%Not Available
Tenderness08.01.08.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tongue discolouration07.14.02.006--Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Tricuspid valve incompetence02.07.05.0010.007059%Not Available
Vasculitis24.05.02.001; 10.02.02.006--
Ventricular septal defect03.07.02.001; 02.04.02.0070.004706%Not Available
Visual impairment06.02.06.0080.004706%Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Muscle strain15.05.07.002; 12.01.07.0040.004706%Not Available
Neonatal hypoxia22.11.02.002; 18.04.15.0020.004706%Not Available
Carotid sinus syndrome17.04.06.001; 24.03.04.002--Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.003--Not Available
Blood pressure inadequately controlled24.06.01.0070.004706%Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Hypertensive nephropathy20.01.08.004; 24.08.05.0030.004706%Not Available
Foetal death18.01.02.003; 08.04.01.0110.003069%
Haemorrhage24.07.01.0020.011765%Not Available
Cerebrovascular insufficiency17.08.02.003; 24.04.06.004--Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages